Abstract
Advances in our understanding of mechanisms of leukemogenesis and driver mutations in acute lymphoblastic leukemia lead to a more precise and informative sub-classification, mainly of B-acute lymphoblastic leukemia. In parallel, in recent years, novel agents have been approved for B-acute lymphoblastic leukemia therapy, and many others are in active clinical research. Among the newly recognized disease subtypes, Philadelphia-chromosome-like acute lymphoblastic leukemia is most heterogeneous and thus, diagnostically challenging. Given that this B-acute lymphoblastic leukemia subtype is associated with a poorer prognosis, improvement of available therapeutic approaches and protocols is a burning issue. We have herein summarized in a clinically relevant manner, up-to-date information regarding diagnostic strategies developed for the identification of patients with Philadelphia-chromosome-like acute lymphoblastic leukemia. Common therapeutic dilemmas, presented as several case scenarios, are also discussed. It is currently acceptable that B-acute lymphoblastic leukemia patients, treated with an aim of cure, irrespective of their age, be evaluated for a Philadelphia-chromosome-like signature as early as possible. Following Philadelphia-chromosome-like recognition, a higher risk for resistance or relapse must be realized and treatment should be modified based on patient9s specific genetic driver and clinical features. However, while active targeted therapeutic options are limited, there is much more to do than just prescribe a matched inhibitor to the identified mutated driver genes. In this review, we present a comprehensive evidence-based approach to the diagnosis and management of Philadelphia-chromosome-like acute lymphoblastic leukemia at different time points during the disease course.

This publication has 110 references indexed in Scilit: